| Article 74 |
Music Streaming Pillow From Zeeq
An earlier study shows music can help people to sleep better. But playing music may disturb others. One can use headphones but they are uncomfortable while sleeping. A pillow from Zeeq can play music with low volume supported by eight wireless speakers, just for you without disturbing others. The product uses iTunes and app in playing music. One can track and optimize their sleep patterns. The product gently vibrates if you snore so that you can wake up and adjust your sleeping position.
About DPP-4 Diabetes Drugs Januvia and Janumet To Lower Blood Sugar Levels
Januvia and Janumet (combination drug of Januvia) are type 2 diabetes (T2D) drugs intended to lower blood sugar levels from Merck franchise. These two drugs are classified as DPP-4 (enzyme dipeptidyl peptidase-4) inhibitors. In a normal individual without type 2 diabetes (T2D), enzyme dipeptidyl peptidase-4 (produced in the body) removes incretin from the human body. If a patient with diabetes is lacking enzyme dipeptidyl peptidase-4, he requires DPP-4 inhibitors to prevent low blood sugar levels and weight gain. Other drugs of this class are
- Squibb from Bristol-Myers
- Onglyza from AstraZeneca
- Galvus (not in the United States) from Novartis
- Tradjenta from Eli Lilly
- Nesina from Takeda
Recently FDA confirmed that the Merck drugs have
- High safety profile
- No risk to major adverse cardiovascular events
- No risk to hospitalization for heart failure
Incretin : Blood glucose levels will be lowered by an increase in insulin production from pancreas due to the stimulation of the group of metabolic hormones called Incretin. There are two important incretin hormones secreted by endocrine cells
- Glucose-dependent insulinotropic peptide, also known as gastric inhibitory peptide (GIP)
- Glucagon-like peptide-1 (GLP-1)
Neovacs Vaccine To Treat Type 1 Diabetes (T1D)
There is a number of companies around the world working on multiple technologies to make the life of a patient with diabetes easier but only a few companies to cure the diabetes autoimmune disease. France based Neovacs biotech company is in the field of developing therapies for autoimmune diseases. The company says they are planning to develop a vaccine for T1D along with researchers from Cochin Hospital in Paris. They are going to conduct a preclinical study in mice models to check the ability of IFN-Kinoid for the treatment of type 1 diabetes (T1D). We have to wait until clinical results were published.
About Omada's Program Intended To Reduce Overweight Or Obesity
Overweight and obesity of senior citizens were reduced by the digital behavioral health coaching program from Omada Health, San Francisco. Previous study has found a direct association between weight gain and risk of chronic diseases such as diabetes and heart diseases. Researchers studied 1,121 adult individuals for three years aged 65 years or above, with baseline body mass index (BMI) of 24 or more with diabetes and heart disease risks. Features of the digital behavioral health coaching program are
- Online educational program for 16 weeks
- To bring behavioral changes
- A social network support group
- A professional health coach for guidance
- Digital tracking tools such as activity tracker and wireless scale
After six months during the program
- At least 9 of the 16 lessons in the program were completed by 90 percent of the participants
- Individuals lost 6.8 percent of body weight on average
- Each individual saved USD 1,770
- Additional savings during the next decade
The above study shows Omada health program gives significant health savings and health outcomes for senior citizens aged 65 or above. HHS announced that Medicare is going to cover Diabetes Prevention Program including digital versions such as Omadas. Sean Duffy is the CEO and co-founder of Omada Health. Cynthia Castro Sweet is one of the study authors and also Director of Medical Affairs.
| Published on October 26, 2016 |
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.